

Roy Bicknell

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2846000/publications.pdf>

Version: 2024-02-01

103
papers

6,526
citations

61984

43
h-index

64796

79
g-index

105
all docs

105
docs citations

105
times ranked

7051
citing authors

#	ARTICLE	IF	CITATIONS
1	Pulmonary MicroRNA Changes Alter Angiogenesis in Chronic Obstructive Pulmonary Disease and Lung Cancer. <i>Biomedicines</i> , 2021, 9, 830.	3.2	9
2	AVEXIS technology identifies novel platelet-leukocyte binding partners including CD148-CD300a. <i>Blood Advances</i> , 2021, 5, 5016-5019.	5.2	1
3	An evaluation of the tumour endothelial marker CLEC14A as a therapeutic target in solid tumours. <i>Journal of Pathology: Clinical Research</i> , 2020, 6, 308-319.	3.0	10
4	CAR T cells targeting tumor endothelial marker CLEC14A inhibit tumor growth. <i>JCI Insight</i> , 2020, 5, .	5.0	23
5	C-type lectin domain group 14 proteins in vascular biology, cancer and inflammation. <i>FEBS Journal</i> , 2019, 286, 3299-3332.	4.7	51
6	Sunitinib Treatment Enhances Metastasis of Innately Drug-Resistant Breast Tumors. <i>Cancer Research</i> , 2017, 77, 1008-1020.	0.9	12
7	Members of the type 14 c-type lectin family protect from inflammatory arthritis but differentially regulate bone erosions. , 2017, , .		0
8	Tube-Forming Assays. <i>Methods in Molecular Biology</i> , 2016, 1430, 149-157.	0.9	11
9	Sprouting angiogenesis is regulated by shedding of the C-type lectin family 14, member A (CLEC14A) ectodomain, catalyzed by rhomboid-like 2 protein (RHBDL2). <i>FASEB Journal</i> , 2016, 30, 2311-2323.	0.5	30
10	Development of Antibody-Based Vaccines Targeting the Tumor Vasculature. <i>Methods in Molecular Biology</i> , 2016, 1403, 839-849.	0.9	0
11	Anti-angiogenic alternatives to VEGF blockade. <i>Clinical and Experimental Metastasis</i> , 2016, 33, 197-210.	3.3	26
12	MCAM and LAMA4 Are Highly Enriched in Tumor Blood Vessels of Renal Cell Carcinoma and Predict Patient Outcome. <i>Cancer Research</i> , 2016, 76, 2314-2326.	0.9	58
13	Glutamate dependent NMDA receptor 2D is a novel angiogenic tumour endothelial marker in colorectal cancer. <i>Oncotarget</i> , 2016, 7, 20440-20454.	1.8	23
14	Robo4 vaccines induce antibodies that retard tumor growth. <i>Angiogenesis</i> , 2015, 18, 83-95.	7.2	15
15	Inference of Low and High-Grade Glioma Gene Regulatory Networks Delineates the Role of Rnd3 in Establishing Multiple Hallmarks of Cancer. <i>PLoS Genetics</i> , 2015, 11, e1005325.	3.5	14
16	In Vivo Evidence for Platelet-Induced Physiological Angiogenesis by a COX Driven Mechanism. <i>PLoS ONE</i> , 2014, 9, e107503.	2.5	13
17	RhoJ interacts with the GIT-PIX complex and regulates focal adhesion disassembly. <i>Journal of Cell Science</i> , 2014, 127, 3039-51.	2.0	51
18	Vascular Targeting Approaches to Treat Cancer. , 2013, , 59-95.		2

#	ARTICLE	IF	CITATIONS
19	Shear stress, tip cells and regulators of endothelial migration. <i>Biochemical Society Transactions</i> , 2011, 39, 1571-1575.	3.4	24
20	Bioinformatic Methods for Finding Differentially Expressed Genes in cDNA Libraries, Applied to the Identification of Tumour Vascular Targets. <i>Methods in Molecular Biology</i> , 2011, 729, 99-119.	0.9	4
21	Hepatitis C Virus Infection Reduces Hepatocellular Polarity in a Vascular Endothelial Growth Factor-Dependent Manner. <i>Gastroenterology</i> , 2010, 138, 1134-1142.	1.3	73
22	The Discovery and Characterisation of Tumour Endothelial Markers. , 2010, , 31-48.		0
23	Active involvement of Robo1 and Robo4 in filopodia formation and endothelial cell motility mediated via WASP and other actin nucleation-promoting factors. <i>FASEB Journal</i> , 2009, 23, 513-522.	0.5	106
24	Anticancer strategies involving the vasculature. <i>Nature Reviews Clinical Oncology</i> , 2009, 6, 395-404.	27.6	234
25	Angiogenic Signalling Pathways. <i>Methods in Molecular Biology</i> , 2009, 467, 3-24.	0.9	67
26	Functionally defining the endothelial transcriptome, from Robo4 to ECSCR. <i>Biochemical Society Transactions</i> , 2009, 37, 1214-1217.	3.4	12
27	Repulsive axon guidance molecule Slit3 is a novel angiogenic factor. <i>Blood</i> , 2009, 114, 4300-4309.	1.4	132
28	Slits and Roundabouts in cancer, tumour angiogenesis and endothelial cell migration. <i>Angiogenesis</i> , 2008, 11, 13-21.	7.2	155
29	Retinal anti-angiogenesis by a new route. <i>Nature Biotechnology</i> , 2008, 26, 528-529.	17.5	1
30	A novel method of differential gene expression analysis using multiple cDNA libraries applied to the identification of tumour endothelial genes. <i>BMC Genomics</i> , 2008, 9, 153.	2.8	47
31	ECSM2, An Endothelial Specific Filamin A Binding Protein That Mediates Chemotaxis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2008, 28, 1640-1646.	2.4	32
32	Neuronal clues to vascular guidance. <i>Experimental Cell Research</i> , 2006, 312, 668-675.	2.6	111
33	Expression of Terminally Glycosylated Calcitonin Receptor-Like Receptor in Uterine Leiomyoma: Endothelial Phenotype and Association with Microvascular Density. <i>Clinical Cancer Research</i> , 2006, 12, 5648-5658.	7.0	9
34	Adrenomedullin and CGRP interact with endogenous calcitonin-receptor-like receptor in endothelial cells and induce its desensitisation by different mechanisms. <i>Journal of Cell Science</i> , 2006, 119, 910-922.	2.0	48
35	Tumour vascular targeting. <i>Nature Reviews Cancer</i> , 2005, 5, 436-446.	28.4	545
36	Antiangiogenic Activity of a Domain Deletion Mutant of Tissue Plasminogen Activator Containing Kringle 2. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2005, 25, 736-741.	2.4	10

#	ARTICLE	IF	CITATIONS
37	Heparin Octasaccharides Inhibit Angiogenesis In vivo. <i>Clinical Cancer Research</i> , 2005, 11, 8172-8179.	7.0	61
38	Soluble Robo4 receptor inhibits in vivo angiogenesis and endothelial cell migration. <i>FASEB Journal</i> , 2005, 19, 121-123.	0.5	162
39	Bone morphogenetic protein 2 (BMP-2) induces in vitro invasion and in vivo hormone independent growth of breast carcinoma cells. <i>International Journal of Oncology</i> , 2005, 27, 401.	3.3	33
40	Vascular Endothelial Growth Factor (VEGF)-D and VEGF-A Differentially Regulate KDR-mediated Signaling and Biological Function in Vascular Endothelial Cells. <i>Journal of Biological Chemistry</i> , 2004, 279, 36148-36157.	3.4	70
41	Therapeutic targeting of the tumor vasculature. <i>Seminars in Radiation Oncology</i> , 2004, 14, 222-232.	2.2	23
42	NOVEL ANGIOGENIC SIGNALING PATHWAYS AND VASCULAR TARGETS. <i>Annual Review of Pharmacology and Toxicology</i> , 2004, 44, 219-238.	9.4	95
43	Therapeutic Inhibition of Angiogenesis. <i>Molecular Biotechnology</i> , 2003, 25, 185-200.	2.4	3
44	The thioredoxin-like fold: Hidden domains in protein disulfide isomerases and other chaperone proteins. <i>BioEssays</i> , 2003, 25, 603-611.	2.5	38
45	EndoPDI, a Novel Protein-disulfide Isomerase-like Protein That Is Preferentially Expressed in Endothelial Cells Acts as a Stress Survival Factor. <i>Journal of Biological Chemistry</i> , 2003, 278, 47079-47088.	3.4	149
46	Transcriptional regulation of the CRLR gene in human microvascular endothelial cells by hypoxia. <i>FASEB Journal</i> , 2003, 17, 1-25.	0.5	72
47	Peptide blockade of HIF α degradation modulates cellular metabolism and angiogenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 10423-10428.	7.1	101
48	Angiogenesis in the Corpus Luteum of Early Pregnancy in the Marmoset and the Effects of Vascular Endothelial Growth Factor Immunoneutralization on Establishment of Pregnancy. <i>Biology of Reproduction</i> , 2002, 67, 1180-1188.	2.7	45
49	Magic Roundabout Is a New Member of the Roundabout Receptor Family That Is Endothelial Specific and Expressed at Sites of Active Angiogenesis. <i>Genomics</i> , 2002, 79, 547-552.	2.9	299
50	ROLE OF THYMIDINE PHOSPHORYLASE IN AN IN VITRO MODEL OF HUMAN BLADDER CANCER INVASION. <i>Journal of Urology</i> , 2002, 167, 1482-1486.	0.4	20
51	Adrenomedullin and the microvasculature. <i>Trends in Pharmacological Sciences</i> , 2002, 23, 101-103.	8.7	39
52	Recent advances in angiogenesis, anti-angiogenesis and vascular targeting. <i>Trends in Pharmacological Sciences</i> , 2002, 23, 576-582.	8.7	130
53	Preparation of the iodine-124 derivative of the Bolton-Hunter reagent ([¹²⁴ I]-SHPP) and its use for labelling a VEGF antibody as a PET tracer. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2002, 45, 1077-1090.	1.0	12
54	Angiogenic co-operation of VEGF and stromal cell TP in endometrial carcinomas. <i>Journal of Pathology</i> , 2002, 196, 416-422.	4.5	50

#	ARTICLE	IF	CITATIONS
55	Adrenomedullin promotes formation of xenografted endometrial tumors by stimulation of autocrine growth and angiogenesis. <i>Oncogene</i> , 2002, 21, 2815-2821.	5.9	102
56	ROLE OF THYMIDINE PHOSPHORYLASE IN AN IN VITRO MODEL OF HUMAN BLADDER CANCER INVASION. <i>Journal of Urology</i> , 2002, , 1482-1486.	0.4	1
57	Targeting Gene Therapy to the Tumor Vasculature. , 2002, , 453-473.		0
58	Delta4, an endothelial specific Notch ligand expressed at sites of physiological and tumor angiogenesis. <i>Differentiation</i> , 2001, 69, 135-144.	1.9	262
59	Therapeutic Inhibition of Angiogenesis. , 2001, 46, 003-026.		1
60	Assessment of Angiogenic Factors: The Chick Chorioallantoic Membrane Assay. , 2001, 58, 119-124.		0
61	Cell Migration and the Boyden Chamber. , 2001, 58, 047-054.		4
62	Steroids and the Endometrium. <i>Current Medicinal Chemistry</i> , 2000, 7, 543-560.	2.4	35
63	Expression of angiogenic factor thymidine phosphorylase and angiogenesis in human atherosclerosis. <i>Journal of Pathology</i> , 2000, 192, 234-242.	4.5	52
64	Suppression of Luteal Angiogenesis in the Primate after Neutralization of Vascular Endothelial Growth Factor ¹ . <i>Endocrinology</i> , 2000, 141, 995-1000.	2.8	189
65	Suppression of Luteal Angiogenesis in the Primate after Neutralization of Vascular Endothelial Growth Factor. <i>Endocrinology</i> , 2000, 141, 995-1000.	2.8	62
66	Transcriptional profiling of human microvascular endothelial cells in the proliferative and quiescent state using cDNA arrays. <i>Angiogenesis</i> , 1999, 3, 211-219.	7.2	29
67	Thymidine phosphorylase expression in endometrial carcinomas. <i>Clinical and Experimental Metastasis</i> , 1999, 17, 445-450.	3.3	23
68	URINARY VASCULAR ENDOTHELIAL GROWTH FACTOR AND ITS CORRELATION WITH BLADDER CANCER RECURRENCE RATES. <i>Journal of Urology</i> , 1999, 161, 799-804.	0.4	118
69	URINARY VASCULAR ENDOTHELIAL GROWTH FACTOR AND ITS CORRELATION WITH BLADDER CANCER RECURRENCE RATES. <i>Journal of Urology</i> , 1999, , 799-804.	0.4	3
70	Angiogenesis in the endometrium. , 1998, 2, 29-35.		17
71	The dormant in vivo phenotype of early stage primary human melanoma: termination by overexpression of vascular endothelial growth factor. <i>Angiogenesis</i> , 1998, 2, 203-217.	7.2	26
72	PCR display identifies tamoxifen induction of the novel angiogenic factor adrenomedullin by a non estrogenic mechanism in the human endometrium. <i>Oncogene</i> , 1998, 16, 409-415.	5.9	125

#	ARTICLE	IF	CITATIONS
73	Role of the hypoxia sensing system, acidity and reproductive hormones in the variability of vascular endothelial growth factor induction in human breast carcinoma cell lines. , 1998, 75, 706-712.		54
74	Validation of anti-vascular endothelial growth factor (anti-VEGF) antibodies for immunohistochemical localization of VEGF in tissue sections: expression of VEGF in the human endometrium. , 1998, 185, 402-408.		66
75	Expression of VEGF in routinely fixed material using a new monoclonal. , 1998, 186, 313-318.		65
76	Thymidine phosphorylase, 2-deoxy-D-ribose and angiogenesis. Biochemical Journal, 1998, 334, 1-8.	3.7	187
77	Expression of VEGF in routinely fixed material using a new monoclonal. Journal of Pathology, 1998, 186, 313-318.	4.5	6
78	Angiogenic Polypeptides in Breast Cancer: Expression of Mrna™s in Primary Human Tumours, MCF-7 Cell Transfection and Xenograft Models. , 1998, , 213-221.		0
79	Regulation of the Expression of the Angiogenic Enzyme Platelet-Derived Endothelial Cell Growth Factor/ Thymidine Phosphorylase in Endometrial Isolates by Ovarian Steroids and Cytokines*. Endocrinology, 1997, 138, 4921-4930.	2.8	28
80	Endothelial Cell-Specific Expression of Tumor Necrosis Factor- α from the KDR or E-Selectin Promoters Following Retroviral Delivery. Human Gene Therapy, 1997, 8, 2239-2247.	2.7	58
81	COS-1 cell expression and one-step affinity protein purification and activity of epitope-tagged human erythropoietin and of site-directed mutants. BBA - Proteins and Proteomics, 1997, 1340, 13-20.	2.1	2
82	Angiopoietins. Angiogenesis, 1997, 1, 15-15.	7.2	0
83	Breast cancer angiogenesis – new approaches to therapy via antiangiogenesis, hypoxic activated drugs, and vascular targeting. Breast Cancer Research and Treatment, 1996, 38, 97-108.	2.5	50
84	Platelet-derived endothelial cell growth factor/thymidine phosphorylase expression in normal tissues: An immunohistochemical study. Journal of Pathology, 1995, 176, 183-190.	4.5	175
85	Expression and mutagenesis of recombinant human and murine erythropoietins in Escherichia coli. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 1995, 1261, 35-43.	2.4	20
86	Regulation of Wnt5a mRNA Expression in Human Mammary Epithelial Cells by Cell Shape, Confluence, and Hepatocyte Growth Factor. Journal of Biological Chemistry, 1995, 270, 12851-12856.	3.4	55
87	Enhancement of Tumor Growth and Vascular Density by Transfection of Vascular Endothelial Cell Growth Factor Into MCF-7 Human Breast Carcinoma Cells. Journal of the National Cancer Institute, 1995, 87, 213-219.	6.3	250
88	Controlling the vasculature: Angiogenesis, anti-angiogenesis and vascular targeting of gene therapy. Trends in Pharmacological Sciences, 1995, 16, 57-66.	8.7	185
89	Gene therapy through signal transduction pathways and angiogenic growth factors as therapeutic targets in breast cancer. Cancer, 1994, 74, 1021-1025.	4.1	34
90	Monoclonal Antibodies That Recognize the Type-2 Activin Receptor, ACTR2. Hybridoma, 1994, 13, 199-203.	0.6	0

#	ARTICLE	IF	CITATIONS
91	Gene therapy through signal transduction pathways and angiogenic growth factors as therapeutic targets in breast cancer. <i>Cancer</i> , 1994, 74, 1021-1025.	4.1	23
92	Angiogenesis in Breast Cancer.. <i>Annals of the New York Academy of Sciences</i> , 1993, 698, 71-84.	3.8	19
93	The isolation and culture of microvascular endothelium. <i>Journal of Cell Science</i> , 1993, 105, 269-273.	2.0	68
94	Expression of platelet-derived endothelial cell growth factor in <i>Escherichia coli</i> and confirmation of its thymidine phosphorylase activity. <i>Biochemistry</i> , 1992, 31, 12141-12146.	2.5	191
95	Novel growth regulatory factors and tumour angiogenesis. <i>European Journal of Cancer & Clinical Oncology</i> , 1991, 27, 781-785.	0.7	141
96	Isolation and properties in culture of human adrenal capillary endothelial cells. <i>Biochemical and Biophysical Research Communications</i> , 1991, 174, 903-908.	2.1	25
97	Interleukin-4 is a potent mitogen for capillary endothelium. <i>Biochemical and Biophysical Research Communications</i> , 1991, 174, 1287-1293.	2.1	95
98	Heterogeneity of the endothelial cell and its role in organ preference of tumour metastasis. <i>Trends in Pharmacological Sciences</i> , 1991, 12, 462-467.	8.7	117
99	Interaction of anions with the active site of carboxypeptidase A. <i>Biochemistry</i> , 1988, 27, 1050-1057.	2.5	40
100	Electronic spectroscopy of cobalt angiotensin converting enzyme and its inhibitor complexes. <i>Biochemistry</i> , 1987, 26, 7291-7297.	2.5	35
101	A spectral study of cobalt(II)-substituted <i>Bacillus cereus</i> phospholipase C. <i>Biochemistry</i> , 1986, 25, 4219-4223.	2.5	20
102	Changes in the coordination geometry of the active-site metal during catalysis of benzylpenicillin hydrolysis by <i>Bacillus cereus</i> .beta.-lactamase II. <i>Biochemistry</i> , 1986, 25, 7208-7215.	2.5	82
103	Protease susceptibility of zinc - and APO-carboxypeptidase A. <i>Biochemical and Biophysical Research Communications</i> , 1985, 133, 787-793.	2.1	24